

Sixth Symposium on Glycosaminoglycans

Antithrombins: From basic research to clinical application

September 8th-10th, 1998

Villa Vigoni, Lovenno (Como) / Italy

Organizers:

Job Harenberg
1st Department of Medicine
Faculty of Clinical Medicine
University of Heidelberg
Theodor-Kutzer-Ufer
D-68167 Mannheim
Germany

Benito Casu
Istituto Scientifico di Chimica
e Biochimica "G. Ronzoni"
Via G. Colombo, 81
I-20133 Milano
Italy

Giancarlo Agnelli
Istituto di Medicina Interna
Università degli Studi di Perugia
Via Enrico dal Pozzo
I-06100 Perugia
Italy

Welcome to Villa Vigoni !

It is the sixth time that the staff of Villa Vigoni hosts our symposium on the action of polysaccharides in molecular biology, pharmacology, vascular endothelium and the relation to arteriosclerosis. Since the knowledge in this field is expanding, the Italian and German colleagues of this research area decided to include a clinical session on the status and perspectives of the clinical application of antithrombins during the meeting.

At the end of each session we have organized round table discussions on selected topics, as outlined in the program. We would like to invite all participants to discuss and comment on these topics. Manuscripts of the presentations may be published in Seminars in Thrombosis and Hemostasis in a separate volume.

Please do not hesitate to contact the organizers of the symposium in the case of difficulties concerning transportation, accommodation or other problems with regard to the symposium.

We thank Professor Roeck and his collaborators for enabling this symposium.

Job Harenberg

Benito Casu

Giancarlo Agnelli

Tuesday, September 8th, 1998

Arrival: until 19.00 p.m.

19.30 *Dinner in Villa Vigoni*

Wednesday, September 9th, 1998

Session I: Recent advances in basic research of thrombin inhibitors

Chairmen: B. Casu, Milano
A. Stemberger, Munich

8.45 -9.00: B. Casu, Milano:
Welcome and introduction

9.00-9.15: M. Petitou, Toulouse:
Rationale for new antithrombotic drugs: bifunctional synthetic pentasaccharide compounds

9.15-9.30: Discussion

9.30-9.45: A. Naggi, Milano:
Modulation of sulfation patterns of heparin

9.45-10.00: R. Porta, Villa Guardia, Como
Antithrombin activities of fucans

10.00-10.15: M. Palumbo, Padova
Interactions of nucleic acid aptamers with thrombin

10.15-10.30: Discussion

10.30-10.45: H. Baumann, Aachen
Influence of regioselective modified heparin derivatives for coating of artificial surfaces and influence on adhesion of selected plasma proteins

10.45-11.00: A. Stemberger, Munich
What is the most effective coating of biomaterials

11.00-11.15: Discussion

11.15-11.30: Coffee break

11.30-11.45: A. Poggi, Santa Maria Imbaro
Antimetastatic effects of glycosaminoglycans and hirudins

11.45-12.00: S. Alban, Regensburg
Anticoagulant properties of glycan sulfates

12.00-12.15: Discussion

12.15-12.30: B. Pöttsch, Bad Nauheim:
Methods for quantification of hirudins

12.30-12.45: L. Piazzolo, Mannheim
Pharmacokinetics of hirudin and PEG-hirudin

12.45-13.00: Discussion

13.00-14.00: Lunch in Villa Vigoni

		Chairmen:	J. Harenberg, Mannheim A. Eldor, Tel-Aviv
Session II:	Recent advances in clinical perspectives of thrombin inhibitors		
Chairmen:	D. Gulba, Berlin G. Agnelli, Perugia		
14.00-14.15:	J. Harenberg, Mannheim Introduction and topics	16.30-16.45:	E. Seifried, Frankfurt New thrombolytic agents
14.15-14.30:	P. Bianchini, Modena Direct and endothelial mediated activities of dermatans	16.45-17.00:	G. Agnelli, Perugia New thrombolytic regime in cardiovascular indications
14.30-14.45:	M. Blank, Tel-Aviv: Pathogenicity of human anti-PF4/heparin in vivo: generation of mouse anti-PF4/heparin and induction of thrombocytopenia by heparin	17.00-17.15:	P. Prandoni, Padova Treatment of venous thromboembolism with low-molecular-weight heparins
14.45-15.00:	G. Huhle, Mannheim Treatment of HIT type II patients	17.15-17.30:	F. Piovella, Pavia Optimal duration of warfarin treatment after an episode of PE/DVT
15.00-15.15:	Discussion	17.30-17.45:	A. K. Kakkar, London Prophylaxis of venous thromboembolism in cancer patients
15.15-15.30:	M. Comeglio, Florence Hirudins for treatment in cardiovascular indications	17.45-18.00:	Discussion: Ranking of drugs or combination of drugs in different clinical indications
15.30-15.45:	A. Eldor, Tel-Aviv Risk assessment models for development of thromboembolic diseases	G. Agnelli:	Summary
15.45-16.00:	D. Gulba, Berlin: GP IIb/IIIa antagonists in cardiovascular indications	19.30	Dinner at Villa Vigoni
16.00-16.15:	Discussion		
16.15-16.30:	Coffee break		

General Information

Publication in Seminars of Thrombosis and Hemostasis, submission of manuscripts on a voluntary basis until January, 31st 1999

Social Program

Tuesday, September 8th, 1998

19.3.0 *Dinner in Villa Vigoni*

Wednesday, September 9th, 1998

8.00-8.45 *Breakfast*

13.00 -14.00 *Lunch in Villa Vigoni*

19.30 : *Dinner in Villa Vigoni*

Thursday, September 10th, 1996

8.00-9.00: *Breakfast*

Departure: *after breakfast*

Location of the Symposium:

"Villa Vigoni e.V."
Via Giulio Vigoni 1
Lovenno di Menaggio
I-22017 Menaggio (Como)
Tel.: +39-344/361 11
Fax: +39-344/36 12 10

Registration: Tuesday, September 8th, 1996

Scientific correspondence:

Job Harenberg
1st Department of Medicine
Faculty of Clinical Medicine
University of Heidelberg
Theodor-Kutzer-Ufer
D-68167 Mannheim
Germany
Tel: +49/621/383-33 78, -27 89
Fax: +49/621/383-38 08
Email: J-Harenberg@t-online.de

This symposium has kindly been supported by

DFG, Deutsche Forschungsgemeinschaft
Alfa Wassermann SpA
Bene Arzneimittel GmbH
Boehringer Mannheim GmbH
Braun Melsungen AG
Crinos Spa
Du Pont Pharma GmbH
Hoechst Marion Roussel Deutschland GmbH
Immuno-Baxter GmbH
Knoll BASF Pharma GmbH
Laboratorio Derivati Organici SpA
Merck KGaA
Novartis Pharma GmbH
Opocrin Spa
Pharmacia & Upjohn GmbH
Rhone Poulenc Rorer GmbH
Sanofi Winthrop GmbH
Thiemann Arzneimittel GmbH